Effects of Pentazocine Versus Lorazepam on Manic Symptoms
| Status: | Completed |
|---|---|
| Conditions: | Schizophrenia, Psychiatric, Psychiatric, Bipolar Disorder |
| Therapuetic Areas: | Psychiatry / Psychology |
| Healthy: | No |
| Age Range: | 18 - 65 |
| Updated: | 3/8/2019 |
| Start Date: | January 2007 |
| End Date: | March 2011 |
Pilot data indicates that pentazocine decreases manic symptoms in hospitalized individuals.
To follow up these initial findings, we plan to conduct a larger, more rigorous, double-blind
study. We will examine whether pentazocine, an agent with kappa-opiate activity, decreases
manic symptoms.
To follow up these initial findings, we plan to conduct a larger, more rigorous, double-blind
study. We will examine whether pentazocine, an agent with kappa-opiate activity, decreases
manic symptoms.
Dysregulation of the opioid system may underlie the pathophysiology of mood disorders, such
as bipolar disorder. Drugs that modulate the opioid system might be effective treatments for
bipolar disorder. The profile and actions of the kappa-opioid system make drugs that target
this system particularly promising as a treatment modality, with relatively low risk of
addictive properties. Pentazocine is an approved drug for pain relief with a good side effect
profile. It is predominantly a kappa opioid agonist with weaker side effects at mu opioid
receptors, at which it is an antagonist. Data from our open-label pilot study of pentazocine
had promising results. We will follow up on these findings with a double-blind,
active-control study of individuals with bipolar disorder or schizoaffective disorder who are
currently hospitalized with acute mania. The antimanic effects of pentazocine will be
compared with an active control (ativan).
as bipolar disorder. Drugs that modulate the opioid system might be effective treatments for
bipolar disorder. The profile and actions of the kappa-opioid system make drugs that target
this system particularly promising as a treatment modality, with relatively low risk of
addictive properties. Pentazocine is an approved drug for pain relief with a good side effect
profile. It is predominantly a kappa opioid agonist with weaker side effects at mu opioid
receptors, at which it is an antagonist. Data from our open-label pilot study of pentazocine
had promising results. We will follow up on these findings with a double-blind,
active-control study of individuals with bipolar disorder or schizoaffective disorder who are
currently hospitalized with acute mania. The antimanic effects of pentazocine will be
compared with an active control (ativan).
Inclusion Criteria:
- bipolar or schizoaffective disorder
- currently manic
- no acute medical issues
- no substance withdrawal
Exclusion Criteria:
- unable to give informed consent
- using opiates for pain management
- history of head injury, dementia, or mental retardation
- seizure disorder
- glaucoma
- unstable cardiac condition or arrhythmia
- moderate-severe pulmonary disease
- pregnancy
We found this trial at
1
site
McLean Hospital McLean Hospital is a comprehensive psychiatric hospital committed to providing easy access to...
Click here to add this to my saved trials
